Glaucoma

While there are many causes of glaucoma, most cases are associated with increased intraocular pressure. Loss of vision is usually characterized by a gradual reduction in peripheral vision, which can lead to a tunnel vision effect. Glaucoma affects approximately 100 million people globally and is one of the leading causes of blindness in the world today. An estimated three million Americans have this sight-threatening disease. Because it is painless and advances gradually, many people who have glaucoma or elevated IOP have not been diagnosed. If detected and treated early, vision can usually be preserved.

What is Glaucoma?

Glaucoma is a common ocular condition whereby damage is caused to the optic nerve connecting the eye to the brain.

What is Open-Angle Glaucoma?

Glaucoma Pathophysiology

Glaucoma Causes

Glaucoma Diagnosis

Glaucoma Management

Glaucoma Classifications

Glaucoma Symptoms

Types of Glaucoma

What is Normal-Tension Glaucoma?

What is Traumatic Glaucoma?

Optic Nerve Cupping in Glaucoma

Latest Glaucoma News and Research

AI-READI consortium launches groundbreaking diabetes data study

Researchers today (Nov. 8, 2024) are releasing the flagship dataset from an ambitious study of biomarkers and environmental factors that might influence the development of type 2 diabetes.

8 Nov 2024

New study identifies potential treatment for tauopathies using carbonic anhydrase inhibitors

Carbonic anhydrase inhibitors show potential in reducing tau protein buildup, offering new therapeutic avenues for neurodegenerative diseases like tauopathies.

4 Nov 2024

Carbonic anhydrase inhibitors clear tau build-up in zebrafish models of tauopathies

A drug commonly used to treat glaucoma has been shown in zebrafish and mice to protect against the build-up in the brain of the protein tau, which causes various forms of dementia and is implicated in Alzheimer’s disease.

4 Nov 2024

Glaucoma medication may help prevent Alzheimer's-related tau build-up

1 Nov 2024

Long-term antiviral treatment may protect vision from shingles

Taking an antiviral medication for a year may prevent vision damage associated with shingles that affects the eye, according to new research led by faculty from the Perelman School of Medicine at the University of Pennsylvania and the NYU Grossman School of Medicine.

21 Oct 2024

Long-term low-dose antiviral treatment reduces eye disease risk from shingles

Long-term, low-dose antiviral treatment reduces the risk for potentially vision-damaging bouts of inflammation and infection, as well as pain, which occur when shingles affects the eye, according to new research presented October 19 at the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago.

20 Oct 2024

Major donation fuels advances in ophthalmic artificial intelligence

The Icahn School of Medicine has announced a $5 million gift from the John and Daria Barry Foundation for the Center for Ophthalmic Artificial Intelligence (AI) and Human Health.

16 Oct 2024

Childhood adversity linked to elevated health risks, differing by sex and stress

Researchers assess the heterogeneous effects of childhood adversity on disease biomarkers and health conditions in adulthood.

20 Sep 2024

Laughter is as good as eye drops in soothing dry eyes, study finds

A study reveals laughter exercise is as effective as artificial tears for dry eye disease, improving symptoms and tear film stability without adverse effects.

16 Sep 2024

Evening versus morning dosing of antihypertensive medications provides no added benefits

In two trials, one in frail elderly patients, evening administration of blood pressure (BP)-lowering medications had no clinical benefits over morning administration, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Timing of blood pressure medication administration does not affect outcomes

Evening administration of blood pressure (BP)-lowering medications did not reduce the risk of cardiovascular events or death compared with morning administration, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024